TrialHuman vaccines & immunotherapeutics2025

Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial.

Xavier Sáez-Llorens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.